A difunctional Pluronic®127-based in situ formed injectable thermogels as prolonged and controlled curcumin depot, fabrication, in vitro characterization and in vivo safety evaluation

Abstract

Curcumin has been reported to be used widely against many types of pathological conditions in clinics. However, due to its limitations such as poor solubility, poor oral absorption and low stability have limited its applications. In the current study, a series of novel chemically cross-linkable depot gel formulations were developed based on thermoresponsive micellar polymer (Pluronic®127) with polyelectrolyte hydrophilic monomer, that is, 2-acrylamido-2-methylpropane sulfonic acid by cold and in situ grafting polymerization method. The formulations were aimed to deliver curcumin at controlled rate from in situ formed depot after administration through subcutaneous route in vivo. The sol-gel phase transitions of formulations were observed by rheological analysis, tube titling and optical transmittance measurements. Maximum swelling of gel formulations was observed at pH 7.4 and below CGT, that is, 25 °C. The in vitro release profile exhibits maximum drug release at pH 7.4 and 25 °C owing to relaxed gel state. In vitro degradation profile of gel formulations showed controlled degradation rate. Cell growth inhibition study confirmed the biocompatibility and safe nature of bare gel formulations against L929 cell lines. In vitro cytotoxic study showed that curcumin loaded in gel formulation has controlled pharmacological activity against HeLa and MCF-7 cancer cells as compared to free drug solution. The IC50 values calculated for pure curcumin solution (30 ± 0.77 µg/ml for HeLa and 27 ± 0.39 µg/ml for MCF-7) were found higher in comparison to curcumin-loaded thermogels against HeLa (19 ± 0.28 µg/ml and 23 ± 0.81 µg/ml) and MCF-7 (22 ± 0.54 µg/ml and 21 ± 0.49 µg/ml). Histopathological and hematological analysis showed the biocompatible nature of hydrogels. Structural confirmation was done by Fourier transform infrared spectroscopy (FTIR) and proton nuclear magnetic resonance spectroscopy (1H NMR). Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) confirmed the thermal stability of the gel formulation. The porous structure of gel formulations was assessed by scanning electron microscopic (SEM) analysis. Results concluded that newly developed gel formulations have thermoresponsive behavior with phase transition at body temperature and can be used as in situ controlled drug depot.